✦ LIBER ✦

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

✍ Scribed by Julie E. Martin; Mark K. Louder; LaSonji A. Holman; Ingelise J. Gordon; Mary E. Enama; Brenda D. Larkin; Charla A. Andrews; Leatrice Vogel; Richard A. Koup; Mario Roederer; Robert T. Bailer; Phillip L. Gomez; Martha Nason; John R. Mascola; Gary J. Nabel; Barney S. Graham

Book ID: 116960945
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 348 KB
Volume: 26
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2008.09.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immune response to vaccination with DNA-

Immune response to vaccination with DNA-hsp65 in a phase I clinical trial with head and neck cancer patients

✍ Victora, G D; Socorro-Silva, A; Volsi, E C; Abdallah, K; Lima, F D; Smith, R B; 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 223 KB

Contribution of influenza immunity and v

Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial

✍ Elisabetta Peduzzi; Nicole Westerfeld; Rinaldo Zurbriggen; Gerd Pluschke; Claudi 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 393 KB

Phase I clinical trial in healthy adults

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens

✍ Arístides Aguilar Betancourt; C.A. González Delgado; Z. Cinza Estévez; J. Cabrer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 227 KB

Erratum to “Cross-subtype antibody and c

Erratum to “Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers” [Vaccine 26 (2008) 1098–1110]

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Lessons from IAVI-006, a Phase I clinica

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 498 KB

Immunological monitoring of in vitro and

Immunological monitoring of in vitro and in vivo immune responses to the Ii-Key/HER2/neu MHC class II peptide vaccine in a phase I clinical trial in breast cancer patients

✍ S. Khoo; C.E. Storrer; K.A. Harris; Y.H. Jama; Z.A. Dehqanzada; C.D. Shriver; E. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB